Get Accurate Results With Our Anticoagulant Therapy Test Kit

Specific Protein Solution
Series	Product Name	Product Name
Anticoagulant Therapy	Heparin	Heparin
Anticoagulant Therapy	Anti-Xa	Anti-Xa

Representing an outstanding group of naturally generated polysaccharide, heparin was termed due to its original isolation from liver tissue one century ago. To date, heparin has been serving as a mainstream anticoagulant medicine in the clinical practice for eight decades since the first human application against thrombotic disorders. Biochemically, the fundamental structure of heparin consists of repeating disaccharide units of uronic acids (L-iduronic or D-glucuronic acid) and N-acetyl-D-glucosamine. Depending on a contained unique pentasaccharide sequence, heparin exerts anticoagulant activity upon binding with antithrombin, in turn to suppress activation of factor Xa and IIa in the coagulation cascade。 Anti-factor Xa heparin is the content of low molecular weight heparin and ordinary heparin in reactive blood by detecting the activity of anti-xa. Heparin is an anticoagulant that inhibits blood clotting. The molecular weight and activity strength of heparin are different. Regular heparin includes a wide range of molecular weight, while low molecular weight heparin includes some heparin molecules with a narrower range and smaller molecular weight. Some of these low-molecular-weight heparins have clinical applications, and there are subtle differences between each. Both regular heparin and low-molecular-weight heparin can be administered intravenously or subcutaneously to patients with thrombosis or precursors. Thrombosis is the body's normal response to damage to blood vessels and tissues. This process involves the initiation of the clotting chain which is the activation of a series of clotting factors and proteins that regulate thrombogenesis. There are many acute and chronic conditions, such as surgery, deep vein thrombosis, and other hypercoagulable diseases - arteriovenous thrombosis, especially in the legs. These clots can block blood flow and cause tissue damage in the affected area. Fragments of the clot fall off and travel to the lungs causing pulmonary embolism; Or it can reach the heart and cause a heart attack. Thrombus clots in pregnant women can sometimes affect blood flow to the fetus and lead to abortion. Heparin interferes with clot formation by accelerating the inhibition of clotting factors (especially Xa and IIa) by acting on proteins called antithrombin. Common heparin affects Xa and IIa, and the activity of inhibiting coagulation factors varies greatly, so it must be closely monitored. Complications include coagulation, excessive bleeding and thrombocytopenia. Conventional heparin therapy is usually administered in the hospital and monitored by activated partial thrombokinase time (PTT) or anti-factor Xa heparin. High-dose heparin therapy is commonly used in surgical procedures such as cardiopulmonary bypass, and efficacy is monitored by activated clotting time (ACT). Low molecular weight heparin is more active against Xa than against IIa and its efficacy is more predictable. Low-molecular-weight heparin therapy is usually performed in outpatients or inpatients, and monitoring is not required for routine treatment. If necessary, efficacy can be observed with anti-factor Xa heparin.

Anticoagulant Therapy Test Kit

Products Details

Featured Products

Contact us